Elite Pharmaceuticals (OTCMKTS:ELTP) Shares Cross Below 200-Day Moving Average - Here's What Happened

Key Points

• Elite Pharmaceuticals' shares crossed below its 200-day moving average, trading as low as $0.36 and last at $0.3631 on volume of 448,844 shares (200‑day MA $0.48).
• The company shows solid recent fundamentals with a market cap of $391.1M, a trailing PE of 12.11, quarterly EPS of $0.01 on $31.59M revenue, a net margin of 30.98% and ROE of 47.93%.
• Headquartered in Houston, Elite is a specialty pharmaceutical company focused on complex dosage forms—including injectables, sterile formulations and oncology therapies—and grows via partnerships and licensing.

Elite Pharmaceuticals Inc. (OTCMKTS:ELTP - Get Free Report)'s share price crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.48 and traded as low as $0.36. Elite Pharmaceuticals shares last traded at $0.3631, with a volume of 448,844 shares changing hands.

Elite Pharmaceuticals Price Performance

The firm has a market capitalization of $391.11 million, a PE ratio of 12.11 and a beta of 0.46. The stock has a 50-day moving average price of $0.39 and a 200 day moving average price of $0.48. The company has a quick ratio of 5.44, a current ratio of 7.34 and a debt-to-equity ratio of 0.05.

Elite Pharmaceuticals (OTCMKTS:ELTP - Get Free Report) last posted its quarterly earnings data on Tuesday, February 17th. The specialty pharmaceutical company reported $0.01 EPS for the quarter. The business had revenue of $31.59 million during the quarter. Elite Pharmaceuticals had a return on equity of 47.93% and a net margin of 30.98%.

Elite Pharmaceuticals Company Profile

Elite Pharmaceuticals, Inc is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.

Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.